After the dual-antibody drug data from Summit Therapeutics (SMMT.US) defeated the "drug king", it was listed as Citigroup's preferred stock and the target price was raised.
Citigroup Maintains Buy on Summit Therapeutics, Raises Price Target to $19
Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $19
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $25
Summit Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Summit Therapeutics' Ivonescimab Outperforms in Trials, Earning Buy Rating and Higher Target Price
Summit Therapeutics Analyst Ratings
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $30
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $16
Summit Therapeutics' Ivonescimab Poised to Outperform KEYTRUDA: A Strong Buy Rating
Summit Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $16 Price Target
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Arcadia Biosciences (RKDA)
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $16
HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $16 Price Target
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $16
Summit Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $16 Price Target
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $16
Summit Therapeutics Analyst Ratings